Safety of lorlatinib in subgroups of patients from a phase I/II trial
E. Felip,B. J. Solomon,B. Besse,T. M. Bauer,R. A. Soo, D. R. Camidge,R. Chiari,A. Bearz,C-C. Lin, S. M. Gadgeel,E-H. Tan,T. Seto,G. R. Oxnard,G. Peltz,A. Abbattista, H. Thurm, F. Toffalorio,S-H. I. Ou,A. T. Shaw Annals of Oncology(2019)
AI 理解论文
溯源树
样例